Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02085538
Other study ID # A5481014
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date May 2014
Est. completion date May 2016

Study information

Verified date April 2018
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Since the amount of palbociclib eliminated in urine is 6.9%, renal impairment is not expected to have much impact on palbociclib. However, the Federal Drug Administration (FDA) Guidance recommends a study in subjects with renal impairment when the drug is likely to be used in patients with impaired renal function. Palbociclib is intended for chronic use in cancer patients who may have some degree of impaired renal function.


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date May 2016
Est. primary completion date May 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Personally signed and dated informed consent document.

- Renal function calculated by the Cockcroft Gault equation: normal function (CLcr >=90 mL/min), mild: CLcr >=60 mL/min and <90 mL/min, moderate: CLcr >=30 mL/min and <60 mL/min, severe: CLcr <30 mL/min but not requiring hemodialysis.

- Subjects with normal renal function matched for age, weight, gender and race to subjects in impaired renal function groups.

Exclusion Criteria:

- Any condition possibly affecting drug absorption.

- Renal allograft recipients.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
palbociclib
palbociclib 125 mg oral capsule with food once
palbociclib
palbociclib 125 mg oral capsule with food once
palbociclib
palbociclib 125 mg oral capsule with food once
palbociclib
palbociclib 125 mg oral capsule with food once

Locations

Country Name City State
United States Avail Clinical Research, LLC DeLand Florida
United States Orlando Clinical Research Center Orlando Florida
United States Prism Research Saint Paul Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)] AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8). 8 days
Primary Maximum Observed Plasma Concentration (Cmax) 8 days
Secondary Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) 8 days
Secondary Apparent Oral Clearance (CL/F) Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. 8 days
Secondary Time to Reach Maximum Observed Plasma Concentration (Tmax) 8 days
Secondary Apparent Volume of Distribution (Vz/F) Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed. 8 days
Secondary Plasma Decay Half-Life (t1/2) Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. 8 days
Secondary Unbound Apparent Oral Clearance (CLu/F) Clearance of unbound drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the oral bioavailability. Unbound drug clearance is a quantitative measure of the rate at which an unbound drug substance is removed from the blood. 8 days
Secondary "Unbound Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)u]" AUC (0 - 8)u= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8)u for unbound drug. It is obtained from AUC (0 - t)u plus AUC (t - 8)u for unbound drug. 8 days
Secondary Unbound Maximum Observed Plasma Concentration (Cmaxu) Cmaxu is the highest measured unbound plasma concentration during the dosing interval. 8 days
Secondary "Unbound Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClastu)" Area under the plasma concentration time-curve from zero to the last measured concentration (AUClastu) for unbound drug. 8 days
Secondary fraction of unbound drug in plasma (fu) fraction of drug in plasma or tissues that is not bound to plasma or tissue proteins. 8 days
Secondary Unbound Apparent Volume of Distribution (Vzu/F) Unbound Volume of distribution is defined as the theoretical volume in which the total unbound amount of drug would need to be uniformly distributed to produce the desired unbound plasma concentration of a drug. Unbound Apparent volume of distribution after oral dose (Vzu/F) is influenced by the fraction absorbed. 8 days
See also
  Status Clinical Trial Phase
Completed NCT01937975 - The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050) Phase 1
Completed NCT03284164 - Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex Phase 1
Completed NCT05992155 - A Study of TAK-279 in Adults With or Without Kidney Problems Phase 1
Completed NCT05004311 - The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics Phase 1
Completed NCT04963738 - A Study of JNJ-73763989 in Adult Participants With Renal Impairment Phase 1
Terminated NCT02508740 - Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment Phase 1
Active, not recruiting NCT01529658 - Renal Hypothermia During Partial Nephrectomy N/A
Terminated NCT00984113 - Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment Phase 1
Completed NCT00750620 - A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment Phase 1
Completed NCT00842868 - The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases N/A
Completed NCT00499187 - Fanconi Syndrome Due to ARVs in HIV-Infected Persons Phase 4
Completed NCT01331941 - A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function Phase 1
Completed NCT05489614 - A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment Phase 1
Completed NCT03259087 - Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005) Phase 1
Completed NCT05086107 - Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment Phase 1
Recruiting NCT05349851 - Bowel Cleansing With Renal Impairment
Completed NCT03660241 - A Renal Impairment Study for PF-04965842 Phase 1
Recruiting NCT06037031 - A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function Phase 1
Completed NCT03289208 - Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment Phase 1
Completed NCT02942810 - To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment Phase 1